Literature DB >> 19574795

Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers.

Simone Marnitz1, Sean Dowdy, Malgorzata Lanowska, Achim Schneider, Karl Podratz, Christhardt Köhler.   

Abstract

OBJECTIVE: Sixty years after exenterative surgery was introduced into gynecologic oncology, the indications and contraindications, techniques, and adjuvant therapies after exenteration are controversially discussed between gynecologic oncologists.
METHODS: To evaluate the current patterns of care, a questionnaire with 48 items was sent to 40 Society of Gynecologic Oncologists member clinics with fellowship programs and all 38 German teaching hospitals for gynecologic oncology.
RESULTS: The mean number of exenterations performed during the last 5 years was comparable in both countries. Consistently, (central) recurrent cervical cancer or persistent tumor after chemoradiation is the main indication. Before exenteration, positron emission tomography-computed tomography is mostly performed in the United States, whereas magnetic resonance imaging is the preferred imaging tool in Germany. Staging is more often done surgically in the United States (61%) compared with Germany (32%). None of the US institutions recommend an exenteration for patients with International Federation of Gynecology and Obstetrics stage IVA in contrast to 43% in Germany. In the case of fistula to the bladder and/or rectum, exenteration was recommended only by 29% and 61% in US and German clinics, respectively. In Germany, interdisciplinarity with general surgeons, urologists, plastic surgeons, and radio-oncologists is more common. There is consensus to apply adjuvant therapy after exenteration in patients with positive margins and/or positive lymph nodes. However, adjuvant therapy is more frequently recommended in Germany (93%) than in the United States (74%).
CONCLUSIONS: Our data reflect considerable differences about indications and contraindications, preoperative staging, and adjuvant therapy for pelvic exenteration between Germany and the United States.

Entities:  

Mesh:

Year:  2009        PMID: 19574795     DOI: 10.1111/IGC.0b013e3181a8351e

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  The effect of body mass index on surgical outcomes and survival following pelvic exenteration.

Authors:  David A Iglesias; Shannon N Westin; Vijayashri Rallapalli; Marilyn Huang; Bryan Fellman; Diana Urbauer; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

2.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

3.  Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.

Authors:  S Marnitz; C Köhler; A Rauer; A Schneider; V Budach; A Tsunoda; M Mangler
Journal:  Strahlenther Onkol       Date:  2013-07-27       Impact factor: 3.621

4.  [Continent urinary diversion following anterior exenteration].

Authors:  R Stein; M G Kamal; P Rubenwolf; A Großmann; C Thomas; J W Thüroff
Journal:  Urologe A       Date:  2015-03       Impact factor: 0.639

5.  Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Authors:  Sota Tanaka; Satoru Nagase; Michiko Kaiho-Sakuma; Tomoyuki Nagai; Hiroki Kurosawa; Masafumi Toyoshima; Hideki Tokunaga; Takeo Otsuki; Hiroki Utsunomiya; Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

6.  Total pelvic exenteration for gynecologic malignancies.

Authors:  Elisabeth J Diver; J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Int J Surg Oncol       Date:  2012-06-10

Review 7.  Angiogenesis and antiangiogenic agents in cervical cancer.

Authors:  Federica Tomao; Anselmo Papa; Luigi Rossi; Eleonora Zaccarelli; Davide Caruso; Federica Zoratto; Pierluigi Benedetti Panici; Silverio Tomao
Journal:  Onco Targets Ther       Date:  2014-12-03       Impact factor: 4.147

8.  Opportunities and Limitations of Pelvic Exenteration Surgery.

Authors:  Björn Lampe; Verónica Luengas-Würzinger; Jürgen Weitz; Stephan Roth; Friederike Rawert; Esther Schuler; Sabrina Classen-von Spee; Nando Fix; Saher Baransi; Anca Dizdar; Peter Mallmann; Klaus-Dieter Schaser; Andreas Bogner
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.